Overview

Ablitech, Inc. develops radical methods for healing the human body by combining cutting edge knowledge and technology in polymer science, molecular biology and medicinal chemistry.

Committed to Healing
     Ablitech has filed for multiple patents protecting Versadel:

     • Method for protecting oligonucleotides for systemic delivery

     • Successful delivery of protected oligonucleotides into cells

     • Active expression of these oligonucleotides in the target cells

Committed to Progress
     The company recently closed on a $700,000 seed capital round composed entirely of Mississippi investors. A $2 million development contract from the Department of Defense has been awarded to the company.

Ablitech History
     In 2005 the concept for Ablitech was conceived by Dr. Nick Hammond and Dr. Lisa Kemp as a result of a National Science Foundation backed program to foster entrepreneurship. The NSF program united two leaders in global research, The University of Mississippi's Medicinal Chemistry Department and The University of Southern Mississippi's School of Polymers and High Performance Materials, where collaborative research founded an idea around a new material for coronary stents winning awards at several regional and national business plan competitions.

In 2007 Ablitech received NSF SBIR Phase I funding, providing not only the initial funding for the development of its radical platform technology, but also a peer reviewed validation of the merit of the technology. Additional NSF SBIR funding granted the initial support for the development of Ablitech's unique gene delivery system – Versadel.